Header Logo

Connection

Martin Maron to Ventricular Function, Left

Back to Details
This is a "connection" page, showing publications Martin Maron has written about Ventricular Function, Left.
Martin Maron
Connection Strength
2.148
Ventricular Function, Left
  1. Wang X, Pabon MA, Makuvire TT, Maimaiti R, Abraham TP, Barriales-Villa R, Claggett BL, Coats CJ, Maron MS, Masri A, Meder B, Nassif ME, Olivotto I, Owens AT, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Malik FI, Wohltman A, Solomon SD, Hegde SM. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM. Circ Heart Fail. 2026 Jan; 19(1):e013918.
    View in: PubMed
    Score: 0.204
  2. Antiochos P, Ge Y, Jerosch-Herold M, David LP, Heydari B, Kolm P, Kim DY, van der Geest RJ, Watkins H, Desai MY, Ho CY, Dolman SF, Desvigne-Nickens P, Maron MS, Schulz-Menger J, Piechnik SK, Appelbaum E, Weintraub WS, Neubauer S, Kramer CM, Kwong RY. Myocardial Entropy and Risk Predictors in Hypertrophic Cardiomyopathy: An Analysis From the NHLBI HCM Registry. Circ Cardiovasc Imaging. 2025 Nov; 18(11):e018031.
    View in: PubMed
    Score: 0.203
  3. Coats CJ, Masri A, Nassif ME, Barriales-Villa R, Arad M, Cardim N, Choudhury L, Claggett B, D?ngen HD, Garcia-Pavia P, Hag?ge AA, Januzzi JL, Lee MMY, Lewis GD, Ma CS, Maron MS, Miao ZM, Michels M, Olivotto I, Oreziak A, Owens AT, Spertus JA, Solomon SD, Tfelt-Hansen J, van Sinttruije M, Veselka J, Watkins H, Jacoby DL, German P, Heitner SB, Kupfer S, Lutz JD, Malik FI, Meng L, Wohltman A, Abraham TP. Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM. J Am Heart Assoc. 2024 Aug 06; 13(15):e035993.
    View in: PubMed
    Score: 0.187
  4. Maron BJ, Rowin EJ, Arkun K, Rastegar H, Larson AM, Maron MS, Chin MT. Adult Monozygotic Twins With Hypertrophic Cardiomyopathy and Identical Disease Expression and Clinical Course. Am J Cardiol. 2020 07 15; 127:135-138.
    View in: PubMed
    Score: 0.139
  5. Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS. Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy. Am J Cardiol. 2020 01 01; 125(1):120-126.
    View in: PubMed
    Score: 0.134
  6. Kalra A, Harris KM, Maron BA, Maron MS, Garberich RF, Haas TS, Lesser JR, Maron BJ. Relation of Doppler Tissue Imaging Parameters With Heart Failure Progression in Hypertrophic Cardiomyopathy. Am J Cardiol. 2016 06 01; 117(11):1808-14.
    View in: PubMed
    Score: 0.105
  7. Rowin EJ, Maron BJ, Kiernan MS, Casey SA, Feldman DS, Hryniewicz KM, Chan RH, Harris KM, Udelson JE, DeNofrio D, Roberts WC, Maron MS. Advanced heart failure with preserved systolic function in nonobstructive hypertrophic cardiomyopathy: under-recognized subset of candidates for heart transplant. Circ Heart Fail. 2014 Nov; 7(6):967-75.
    View in: PubMed
    Score: 0.094
  8. Caselli S, Maron MS, Urbano-Moral JA, Pandian NG, Maron BJ, Pelliccia A. Differentiating left ventricular hypertrophy in athletes from that in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2014 Nov 01; 114(9):1383-9.
    View in: PubMed
    Score: 0.094
  9. Malik R, Maron MS, Rastegar H, Pandian NG. Hypertrophic cardiomyopathy with right ventricular outflow tract and left ventricular intracavitary obstruction. Echocardiography. 2014 May; 31(5):682-5.
    View in: PubMed
    Score: 0.091
  10. Urbano-Moral JA, Rowin EJ, Maron MS, Crean A, Pandian NG. Investigation of global and regional myocardial mechanics with 3-dimensional speckle tracking echocardiography and relations to hypertrophy and fibrosis in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014 Jan; 7(1):11-9.
    View in: PubMed
    Score: 0.089
  11. Williams LK, Urbano-Moral JA, Rowin EJ, Jamorski M, Bruchal-Garbicz B, Carasso S, Pandian NG, Maron MS, Rakowski H. Velocity vector imaging in the measurement of left ventricular myocardial mechanics on cardiac magnetic resonance imaging: correlations with echocardiographically derived strain values. J Am Soc Echocardiogr. 2013 Oct; 26(10):1153-1162.
    View in: PubMed
    Score: 0.087
  12. Pelliccia A, Maron MS, Maron BJ. Assessment of left ventricular hypertrophy in a trained athlete: differential diagnosis of physiologic athlete's heart from pathologic hypertrophy. Prog Cardiovasc Dis. 2012 Mar-Apr; 54(5):387-96.
    View in: PubMed
    Score: 0.079
  13. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012 Feb 01; 14:13.
    View in: PubMed
    Score: 0.079
  14. Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. Am J Cardiol. 2010 Jun 15; 105(12):1842-3.
    View in: PubMed
    Score: 0.070
  15. Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, Lesser JR, Udelson JE, Manning WJ, Maron BJ. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008 Sep; 1(3):184-91.
    View in: PubMed
    Score: 0.061
  16. Hegde SM, Wang X, Garcia-Pavia P, Getchevski S, Masri A, Merkely B, Nassif ME, Pe?a-Pe?a ML, Barriales-Villa R, Bilen O, Burroughs M, Claggett B, Costabel JP, Correia EB, Dybro AM, Elliott P, Lakdawala NK, Mann A, Maron MS, Nair A, Poulsen SH, Reant P, Schulze PC, Wang A, Sohn R, Berhane I, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Wohltman A, Fifer MA, Solomon SD. Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM. J Am Coll Cardiol. 2025 Dec 16; 86(24):2452-2467.
    View in: PubMed
    Score: 0.050
  17. Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, Oreziak A, Owens AT, Tower-Rader A, Rader F, Garcia-Pavia P, Olivotto I, Coats CJ, Fifer MA, Sherrid MV, Solomon SD, Watkins H, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Melloni C, Meng L, Wei J, Maron MS, Masri A. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM. JACC Heart Fail. 2025 Aug; 13(8):102496.
    View in: PubMed
    Score: 0.050
  18. Davis BJ, Volk H, Nguyen O, Kamna D, Chen H, Barriales-Villa R, Garcia-Pavia P, Olivotto I, Owens AT, Coats CJ, Abraham TP, Solomon SD, Maron MS, Masri A. Safety and Efficacy of Mavacamten and Aficamten in Patients With Hypertrophic Cardiomyopathy. J Am Heart Assoc. 2025 Mar 18; 14(6):e038758.
    View in: PubMed
    Score: 0.049
  19. Massera D, Sherrid MV, Adlestein E, Bokhari N, Alvarez IC, Wu WY, Reuter MC, Maron MS, Maron BJ, Rowin EJ. Disopyramide Revisited for Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy: Efficacy and Safety in Patients Treated for at Least 5?Years. J Am Heart Assoc. 2025 Jan 21; 14(2):e037639.
    View in: PubMed
    Score: 0.048
  20. Hegde SM, Claggett BL, Wang X, Jering K, Prasad N, Roshanali F, Masri A, Nassif ME, Barriales-Villa R, Abraham TP, Cardim N, Coats CJ, Kramer CM, Maron MS, Michels M, Olivotto I, Saberi S, Jacoby DL, Heitner SB, Kupfer S, Meng L, Wohltman A, Malik FI, Solomon SD. Impact of Aficamten on Echocardiographic Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2024 Nov 05; 84(19):1789-1802.
    View in: PubMed
    Score: 0.047
  21. Masri A, Sherrid MV, Abraham TP, Choudhury L, Garcia-Pavia P, Kramer CM, Barriales-Villa R, Owens AT, Rader F, Nagueh SF, Olivotto I, Saberi S, Tower-Rader A, Wong TC, Coats CJ, Watkins H, Fifer MA, Solomon SD, Heitner SB, Jacoby DL, Kupfer S, Malik FI, Meng L, Sohn RL, Wohltman A, Maron MS. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4. J Card Fail. 2024 11; 30(11):1439-1448.
    View in: PubMed
    Score: 0.046
  22. Heydari B, Satriano A, Jerosch-Herold M, Kolm P, Kim DY, Cheng K, Choi YL, Antiochos P, White JA, Mahmod M, Chan K, Raman B, Desai MY, Ho CY, Dolman SF, Desvigne-Nickens P, Maron MS, Friedrich MG, Schulz-Menger J, Piechnik SK, Appelbaum E, Weintraub WS, Neubauer S, Kramer CM, Kwong RY. 3-Dimensional Strain Analysis of?Hypertrophic Cardiomyopathy: Insights From the NHLBI International HCM Registry. JACC Cardiovasc Imaging. 2023 04; 16(4):478-491.
    View in: PubMed
    Score: 0.042
  23. Sharkey SW, Kalra A, Henry TD, Smith TD, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ. Coexistence of acute takotsubo syndrome and acute coronary syndrome. Catheter Cardiovasc Interv. 2020 10 01; 96(4):825-829.
    View in: PubMed
    Score: 0.034
  24. Weissler-Snir A, Hindieh W, Gruner C, Fourey D, Appelbaum E, Rowin E, Care M, Lesser JR, Haas TS, Udelson JE, Manning WJ, Olivotto I, Tomberli B, Maron BJ, Maron MS, Crean AM, Rakowski H, Chan RH. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (?-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy. Circ Cardiovasc Imaging. 2017 Feb; 10(2).
    View in: PubMed
    Score: 0.028
  25. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012 Jan; 5(1):119-22.
    View in: PubMed
    Score: 0.020
  26. Han Y, Osborn EA, Maron MS, Manning WJ, Yeon SB. Impact of papillary and trabecular muscles on quantitative analyses of cardiac function in hypertrophic cardiomyopathy. J Magn Reson Imaging. 2009 Nov; 30(5):1197-202.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.